AUA 2017: Early Cardiovascular Morbidity in a Pilot Prospective Randomized Trial Comparing LHRH Agonist and Antagonist Among Patients with Advanced Prostate Cancer.
Boston, MA (UroToday.com) Dr. Pinthus presented on the relationship early cardiovascular morbidity in patients with advanced prostate cancer receiving LHRH agonists and antagonists. Dr. Pinthus and colleagues found interest in this topic because recent data has suggested that LHRH-antagonists may be associated with lower risks of cardiovascular events comparted to LHRH-agonist. They propose that this increased cardiovascular morbidity is associated with an increase in FSH increasing atherosclerosis.
AUA 2017: Relationship Between Quality of Life and Overall Survival in Metastatic Castration-Resistant Prostate cancer patients in ALSYMPCA: Analysis by Prior Docetaxel Subgroup
Boston, MA (UroToday.com) Dr. Shore presented on the relationship between quality of live and overall survival in metastatic castrate-resistant prostate cancer patients with Radium-223 administration analyzed by prior docetaxel. Using the functional assessment of cancer therapy-prostate (FACT-P) they were able to create a time dependent model for change in health-related quality of life scores.
AUA 2017: Population-based analysis in treatment toxicity among men with castration-resistant prostate cancer
Boston, MA (UroToday.com) Dr. Nam presented on the treatment toxicity in men with castrate resistant prostate cancer. By performing a population based analysis of over 2400 men in Ontario, Canada they were able to describe the toxicity and overall survival. All men were treated with contemporary treatments including abiraterone, enzalutamide, docetaxel or cabazitaxel for castrate resistant prostate cancer.
AUA 2017: Novel therapies targeting androgen receptor variant in an in vitro model of castrate resistant prostate cancer.
Boston, MA (UroToday.com) Joseph Baiocco presented on novel therapies targeting the androgen receptor variants in an in vivo model of castrate resistant prostate cancer. This study emphasized the importance of being able to provide further treatment for patients with androgen receptor variants in the setting of castrate resistant prostate cancer.
AUA 2017: Risk of hospitalization following outpatient prostate brachytherapy
Boston, MA (UroToday.com) This study evaluated the short term complication rates after brachytherapy of the prostate. Using the Healthcare Cost and Utilization Project Database for California, the authors found hospital visits by 7% of the patients within 30 days from brachytherapy. Of those, 20.2% resulted in inpatient admission.
AUA 2017: Prostate fiducial marker placement in patients while on anticoagulation: feasibility prior to prostate SBRT
Boston, MA (UroToday.com) The authors of this study evaluated the safety of continuing anticoagulation for patients undergoing TRUS fiducial marker placement. In a consecutive series of 23 patients, no bleeding complication was encountered. As such, the authors concluded that active anticoagulation is not an absolute contraindication for fiducial marker placement.
AUA 2017: Long-term Survival in Men with Gleason Score 9-10 Treated with Prostate Brachytherapy and External Beam Irradiation
Boston, MA (UroToday.com) This study attempts to address an important question: whether high risk prostate cancer is better treated with RP or combined radiation therapy following neoadjuvant ADT. The authors retrospectively reviewed the clinical course in patients with high risk prostate cancer as defined by the D’Amico risk categories, who underwent RP or combined external-beam radiation and high dose-rate brachytherapy.